vs

Side-by-side financial comparison of OCULAR THERAPEUTIX, INC (OCUL) and PARKE BANCORP, INC. (PKBK). Click either name above to swap in a different company.

PARKE BANCORP, INC. is the larger business by last-quarter revenue ($22.7M vs $13.3M, roughly 1.7× OCULAR THERAPEUTIX, INC). PARKE BANCORP, INC. runs the higher net margin — 48.8% vs -488.0%, a 536.7% gap on every dollar of revenue. On growth, PARKE BANCORP, INC. posted the faster year-over-year revenue change (35.7% vs -22.4%). PARKE BANCORP, INC. produced more free cash flow last quarter ($39.0M vs $-57.1M). Over the past eight quarters, PARKE BANCORP, INC.'s revenue compounded faster (22.6% CAGR vs -5.3%).

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

Parke Bancorp, Inc. is a U.S. regional bank holding company operating Parke Bank. It offers commercial and retail banking services including deposit products, mortgage loans, small business financing and personal lending, primarily serving customers across New Jersey and the Philadelphia metropolitan area.

OCUL vs PKBK — Head-to-Head

Bigger by revenue
PKBK
PKBK
1.7× larger
PKBK
$22.7M
$13.3M
OCUL
Growing faster (revenue YoY)
PKBK
PKBK
+58.1% gap
PKBK
35.7%
-22.4%
OCUL
Higher net margin
PKBK
PKBK
536.7% more per $
PKBK
48.8%
-488.0%
OCUL
More free cash flow
PKBK
PKBK
$96.0M more FCF
PKBK
$39.0M
$-57.1M
OCUL
Faster 2-yr revenue CAGR
PKBK
PKBK
Annualised
PKBK
22.6%
-5.3%
OCUL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OCUL
OCUL
PKBK
PKBK
Revenue
$13.3M
$22.7M
Net Profit
$-64.7M
$11.1M
Gross Margin
88.0%
Operating Margin
-526.5%
64.2%
Net Margin
-488.0%
48.8%
Revenue YoY
-22.4%
35.7%
Net Profit YoY
-33.6%
49.8%
EPS (diluted)
$-0.27
$0.93

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OCUL
OCUL
PKBK
PKBK
Q4 25
$13.3M
$22.7M
Q3 25
$14.5M
$21.0M
Q2 25
$13.5M
$18.7M
Q1 25
$10.7M
$17.4M
Q4 24
$17.1M
$16.8M
Q3 24
$15.4M
$15.6M
Q2 24
$16.4M
$15.5M
Q1 24
$14.8M
$15.1M
Net Profit
OCUL
OCUL
PKBK
PKBK
Q4 25
$-64.7M
$11.1M
Q3 25
$-69.4M
$10.6M
Q2 25
$-67.8M
$8.3M
Q1 25
$-64.1M
$7.8M
Q4 24
$-48.4M
$7.4M
Q3 24
$-36.5M
$7.5M
Q2 24
$-43.8M
$6.5M
Q1 24
$-64.8M
$6.2M
Gross Margin
OCUL
OCUL
PKBK
PKBK
Q4 25
88.0%
Q3 25
87.8%
Q2 25
85.6%
Q1 25
88.2%
Q4 24
92.8%
Q3 24
89.9%
Q2 24
90.8%
Q1 24
91.0%
Operating Margin
OCUL
OCUL
PKBK
PKBK
Q4 25
-526.5%
64.2%
Q3 25
-472.3%
64.2%
Q2 25
-502.6%
59.0%
Q1 25
-597.5%
59.1%
Q4 24
-296.1%
58.0%
Q3 24
-298.2%
60.2%
Q2 24
-265.1%
56.7%
Q1 24
-214.0%
55.4%
Net Margin
OCUL
OCUL
PKBK
PKBK
Q4 25
-488.0%
48.8%
Q3 25
-477.3%
50.6%
Q2 25
-503.9%
44.3%
Q1 25
-598.7%
44.6%
Q4 24
-283.3%
44.2%
Q3 24
-236.6%
48.1%
Q2 24
-266.3%
41.6%
Q1 24
-438.9%
40.7%
EPS (diluted)
OCUL
OCUL
PKBK
PKBK
Q4 25
$-0.27
$0.93
Q3 25
$-0.38
$0.89
Q2 25
$-0.39
$0.69
Q1 25
$-0.38
$0.65
Q4 24
$-0.25
$0.61
Q3 24
$-0.22
$0.62
Q2 24
$-0.26
$0.53
Q1 24
$-0.49
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OCUL
OCUL
PKBK
PKBK
Cash + ST InvestmentsLiquidity on hand
$737.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$654.3M
$324.5M
Total Assets
$808.1M
$2.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OCUL
OCUL
PKBK
PKBK
Q4 25
$737.1M
Q3 25
$344.8M
Q2 25
$391.1M
Q1 25
$349.7M
Q4 24
$392.1M
Q3 24
$427.2M
Q2 24
$459.7M
Q1 24
$482.9M
Stockholders' Equity
OCUL
OCUL
PKBK
PKBK
Q4 25
$654.3M
$324.5M
Q3 25
$258.2M
$314.8M
Q2 25
$305.9M
$312.2M
Q1 25
$265.9M
$305.9M
Q4 24
$315.3M
$300.1M
Q3 24
$352.0M
$296.5M
Q2 24
$377.7M
$292.8M
Q1 24
$408.0M
$288.4M
Total Assets
OCUL
OCUL
PKBK
PKBK
Q4 25
$808.1M
$2.2B
Q3 25
$410.9M
$2.2B
Q2 25
$451.3M
$2.2B
Q1 25
$405.9M
$2.1B
Q4 24
$457.9M
$2.1B
Q3 24
$490.4M
$2.1B
Q2 24
$517.1M
$2.0B
Q1 24
$538.9M
$2.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OCUL
OCUL
PKBK
PKBK
Operating Cash FlowLast quarter
$-54.2M
$39.6M
Free Cash FlowOCF − Capex
$-57.1M
$39.0M
FCF MarginFCF / Revenue
-430.9%
171.3%
Capex IntensityCapex / Revenue
21.4%
2.6%
Cash ConversionOCF / Net Profit
3.57×
TTM Free Cash FlowTrailing 4 quarters
$-216.9M
$63.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OCUL
OCUL
PKBK
PKBK
Q4 25
$-54.2M
$39.6M
Q3 25
$-50.7M
$11.4M
Q2 25
$-55.2M
$6.8M
Q1 25
$-44.7M
$7.0M
Q4 24
$-39.4M
$35.2M
Q3 24
$-36.6M
$9.4M
Q2 24
$-24.8M
$8.9M
Q1 24
$-33.9M
$8.3M
Free Cash Flow
OCUL
OCUL
PKBK
PKBK
Q4 25
$-57.1M
$39.0M
Q3 25
$-56.7M
$11.2M
Q2 25
$-56.5M
$6.7M
Q1 25
$-46.6M
$6.6M
Q4 24
$-39.6M
$35.0M
Q3 24
$-36.6M
$9.4M
Q2 24
$-25.5M
$8.9M
Q1 24
$-34.1M
$8.3M
FCF Margin
OCUL
OCUL
PKBK
PKBK
Q4 25
-430.9%
171.3%
Q3 25
-390.0%
53.5%
Q2 25
-419.7%
35.8%
Q1 25
-435.6%
38.0%
Q4 24
-232.0%
209.1%
Q3 24
-237.6%
60.0%
Q2 24
-155.4%
57.1%
Q1 24
-231.1%
55.1%
Capex Intensity
OCUL
OCUL
PKBK
PKBK
Q4 25
21.4%
2.6%
Q3 25
41.2%
0.5%
Q2 25
9.3%
0.3%
Q1 25
18.1%
2.2%
Q4 24
1.2%
0.7%
Q3 24
0.6%
0.1%
Q2 24
4.5%
0.2%
Q1 24
1.7%
0.1%
Cash Conversion
OCUL
OCUL
PKBK
PKBK
Q4 25
3.57×
Q3 25
1.07×
Q2 25
0.82×
Q1 25
0.90×
Q4 24
4.75×
Q3 24
1.25×
Q2 24
1.38×
Q1 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons